We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Salvage Therapy of Multiple Myeloma: The New Generation Drugs.
- Authors
Romano, Alessandra; Conticello, Concetta; Cavalli, Maide; Vetro, Calogero; Di Raimondo, Cosimo; Di Martina, Valentina; Schinocca, Elena; La Fauci, Alessia; Parrinello, Nunziatina Laura; Chiarenza, Annalisa; Di Raimondo, Francesco
- Abstract
During the past decade, overall results of treatment of multiple myeloma (MM) have been improved and survival curves are now significantly better with respect to those obtainedwith historical treatment. These improvements are linked to a deeper knowledge of the biology of disease and to the introduction in clinical practice of drugs with different mechanism of action such as proteasome inhibitors and immunomodulatory drugs (IMiDs). However, MM remains in most cases an incurable disease. For patients who relapse after treatment with novel agents, the prognosis is dismal and newdrugs and therapeutic strategies are required for continued disease control. In this review, we summarize new insights in salvage therapy for relapsed/refractory MMas emerging from recent clinical trials exploring the activity of bendamustine, new generation proteasome inhibitors, novel IMiDs, monoclonal antibodies, and drugs interfering with growth pathways.
- Publication
BioMed Research International, 2014, Vol 2014, p1
- ISSN
2314-6133
- Publication type
Article
- DOI
10.1155/2014/456037